ATPW
MRKR icon

Ashton Thomas Private Wealth’s Marker Therapeutics MRKR Stock Holding History

Ashton Thomas Private Wealth’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.1K Hold
16,400
– – ﹤0.01% 1429
2026
Q1 		$21.3K Buy
16,400
+6,400
+64% +$10.2K ﹤0.01% 1348
2025
Q4 		$14.9K Hold
10,000
– – ﹤0.01% 995
2025
Q3 		$8.93K Buy
+10,000
New +$12.3K ﹤0.01% 965

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
CIA
Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return

Ashton Thomas Private Wealth's MRKR Position: Q2 2026 in Review

Ashton Thomas Private Wealth held its Marker Therapeutics (MRKR) position steady in Q2 2026 at 16,400 shares worth $24.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1429.

Ashton Thomas Private Wealth first reported a position in MRKR in Q3 2025 and has held it in 4 quarters since. 35 funds tracked by Wall St. Rank hold MRKR as of Q2 2026.

  • Ashton Thomas Private Wealth held 16,400 shares of Marker Therapeutics worth $24.1K as of Q2 2026.
  • Ashton Thomas Private Wealth left its Marker Therapeutics share count unchanged in Q2 2026.
  • Marker Therapeutics made up ﹤0.01% of Ashton Thomas Private Wealth's portfolio in Q2 2026, its #1429 holding.
  • Ashton Thomas Private Wealth first reported a position in Marker Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 35 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2026.

Based on Ashton Thomas Private Wealth's 13F filing for Q2 2026, filed 29 Jul 2026.